INVENTIVA ADS/1 O.N. - Asset Resilience Ratio
INVENTIVA ADS/1 O.N. (6IVA) has an Asset Resilience Ratio of 52.73% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6IVA net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how INVENTIVA ADS/1 O.N.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see INVENTIVA ADS/1 O.N. balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down INVENTIVA ADS/1 O.N.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 6IVA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €131.56 Million | 52.73% |
| Total Liquid Assets | €131.56 Million | 52.73% |
Asset Resilience Insights
- Very High Liquidity: INVENTIVA ADS/1 O.N. maintains exceptional liquid asset reserves at 52.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
INVENTIVA ADS/1 O.N. Industry Peers by Asset Resilience Ratio
Compare INVENTIVA ADS/1 O.N.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for INVENTIVA ADS/1 O.N. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for INVENTIVA ADS/1 O.N..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.73% | €131.56 Million ≈ $153.81 Million |
€249.51 Million ≈ $291.70 Million |
-- |
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€118.97 Million ≈ $139.08 Million |
-- |
| 2023-12-31 | 0.10% | €70.00K ≈ $81.84K |
€69.56 Million ≈ $81.32 Million |
-0.80pp |
| 2022-12-31 | 0.90% | €1.05 Million ≈ $1.23 Million |
€116.00 Million ≈ $135.62 Million |
-6.33pp |
| 2021-12-31 | 7.24% | €8.83 Million ≈ $10.32 Million |
€121.98 Million ≈ $142.61 Million |
-- |
About INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more